Saratoga Health & Biotechnology Portfolio C (SHPCX)
12.82
-0.11
(-0.85%)
USD |
Jul 07 2025
Key Stats
Customize
Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
---|---|---|---|
3.32% | 10.08M | 1.08% | 17.00% |
1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
-1.622M | -2.43% | Upgrade | Upgrade |
Basic Info
Investment Strategy | |
The Fund seeks long-term growth of capital through selective investment in the securities of companies engaged in the health care, health products, pharmaceuticals, research and biotechnology research development and implementation and other areas related to the health industry. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Health/Biotechnology Funds |
Fund Owner Firm Name | Saratoga |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
22
-855.68M
Peer Group Low
19.37M
Peer Group High
1 Year
% Rank:
18
-1.622M
-2.481B
Peer Group Low
10.00M
Peer Group High
3 Months
% Rank:
17
-1.293B
Peer Group Low
15.94M
Peer Group High
3 Years
% Rank:
20
-6.960B
Peer Group Low
87.29M
Peer Group High
6 Months
% Rank:
18
-1.663B
Peer Group Low
10.00M
Peer Group High
5 Years
% Rank:
26
-6.729B
Peer Group Low
4.689B
Peer Group High
YTD
% Rank:
18
-1.663B
Peer Group Low
10.00M
Peer Group High
10 Years
% Rank:
32
-12.22B
Peer Group Low
5.565B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of July 08, 2025.
Asset Allocation
As of April 30, 2025.
Type | % Net |
---|---|
Cash | 1.04% |
Stock | 98.10% |
Bond | 0.86% |
Convertible | 0.00% |
Preferred | 0.00% |
Other | 0.00% |
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
McKesson Corp | 6.79% | 735.33 | 2.23% |
Dreyfus Inst Preferred Govt Money Market Fund Inst | 5.73% | 1.00 | 0.00% |
Amgen Inc | 5.70% | 292.95 | -1.77% |
Cencora Inc | 5.53% | 302.50 | 2.12% |
Exelixis Inc | 5.29% | 44.16 | -4.31% |
Cardinal Health Inc | 5.26% | 167.63 | 1.64% |
United Therapeutics Corp | 4.43% | 290.39 | -1.39% |
The Cigna Group | 4.31% | 313.63 | -1.91% |
Novartis AG | 4.30% | 122.12 | 0.18% |
Intuitive Surgical Inc | 4.25% | 534.71 | -1.79% |
Fees & Availability
Fees | |
Actual 12B-1 Fee | 1.00% |
Actual Management Fee | 1.25% |
Administration Fee | 3.60K% |
Maximum Front Load | -- |
Maximum Deferred Load | 1.00% |
Maximum Redemption Fee | 0.00% |
General Availability | |
Available for Insurance Product | -- |
Available for RRSP | -- |
Purchase Details | |
Open to New Investors |
|
Minimum Initial Investment | 250.00 None |
Minimum Subsequent Investment | 0.00 None |
Basic Info
Investment Strategy | |
The Fund seeks long-term growth of capital through selective investment in the securities of companies engaged in the health care, health products, pharmaceuticals, research and biotechnology research development and implementation and other areas related to the health industry. |
General | |
Security Type | Mutual Fund |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Global Peer Group | Equity Sector Healthcare |
Peer Group | Health/Biotechnology Funds |
Global Macro | Equity Industry Sector |
US Macro | Sector Equity Funds |
YCharts Categorization | -- |
YCharts Benchmark | -- |
Prospectus Objective | Health/Biotechnology Funds |
Fund Owner Firm Name | Saratoga |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Fundamentals
General | |
Distribution Yield | -- |
Dividend Yield TTM (7-3-25) | 0.00% |
30-Day SEC Yield | -- |
7-Day SEC Yield | -- |
Stock | |
Weighted Average PE Ratio | 28.80 |
Weighted Average Price to Sales Ratio | 3.870 |
Weighted Average Price to Book Ratio | 7.712 |
Weighted Median ROE | 35.95% |
Weighted Median ROA | 6.95% |
ROI (TTM) | 11.67% |
Return on Investment (TTM) | 11.67% |
Earning Yield | 0.0434 |
LT Debt / Shareholders Equity | 2.256 |
As of April 30, 2025
Growth Metrics
EPS Growth (1Y) | 17.98% |
EPS Growth (3Y) | 6.08% |
EPS Growth (5Y) | 6.35% |
Sales Growth (1Y) | 11.79% |
Sales Growth (3Y) | 9.40% |
Sales Growth (5Y) | 10.83% |
Sales per Share Growth (1Y) | 14.62% |
Sales per Share Growth (3Y) | 11.44% |
Operating Cash Flow - Growth Ratge (3Y) | 4.14% |
As of April 30, 2025
Fund Details
Top Portfolio Holders
Name | % Weight |
---|---|
Portfolio A | 5.00% |
Portfolio B | 3.50% |
Portfolio C | 2.25% |
Excel Add-In Codes
Name: =YCI("M:SHPCX", "name") |
Broad Asset Class: =YCI("M:SHPCX", "broad_asset_class") |
Broad Category: =YCI("M:SHPCX", "broad_category_group") |
Prospectus Objective: =YCI("M:SHPCX", "prospectus_objective") |
To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |